IE Circular No. 79-01, Administration of Unauthorized Byproduct Material to Humans
CR79001
Jan 5 1979
MEMORANDUM FOR: B. H. Grier, Director, Region I
J. P. O'Reilly, Director, Region II
J. G. Keppler, Director, Region III
K. V. Seyfrit, Director, Region IV
R. H. Engelken, Director, Region V
FROM: James H. Sniezek, Director, Division of Resident and
Regional Reactor Inspection, IE
SUBJECT: IE CIRCULAR NO 79-01, ADMINISTRATION OF UNAUTHORIZED
BYPRODUCT MATERIAL TO HUMANS
The subject circular is transmitted of issuance on January 12, 1979. The
circular should be issued to all medical licensees except teletherapy
medical licensees and to all radiopharmaceutical suppliers in your Region.
Enclosed is a draft copy of the transmittal letter and two removable labels
for each licensee who is to receive this circular. One label is for the
draft transmittal letter and the other label is for the envelope.
James H. Sniezek, Director
Division of Fuel Facilities and
Materials Safety Inspection
Office of Inspection and Enforcement
Enclosures:
1. Draft transmittal letter
2. IE Circular No. 79-01
3. Removable Addressee Labels
CONTACT: E. D. Flack, IE
49-28188
.
(Transmittal letter for IE Circular 79-01, to each medical licensee except
teletherapy licensees and each radiopharmaceutical supplier)
IE Circular No. 79-01
Addressee:
The enclosed IE Circular 79-01, is forwarded to you for information. If
there are any questions related to your understanding of the suggested
actions, please contact this office.
Signature
(Regional Director)
Enclosures:
1. IE Circular No. 79-01
2. List of IE Circulars
Issued in 1978
.
NUCLEAR REGULATORY COMMISSION
OFFICE OF INSPECTION AND ENFORCEMENT
WASHINGTON, D. C. 20555
January 12, 1979
IE Circular No. 79-01
ADMINISTRATION OF UNAUTHORIZED BYPRODUCT MATERIAL TO HUMANS
Description of Circumstances:
Recently the U. S. Nuclear Regulatory Commission (NRC) has investigated two
incidents in which reagent grade compounds containing byproduct material
were administered as intravenous radiopharmaceutical to humans. These
compounds had neither been manufactured for use as radiopharmaceutical nor
undergone testing for human use.
In these incidents the byproduct materials were in chemical forms other that
the forms used in diagnostic studies and should not have been shipped by the
supplier. In one case Selenium-75 labeled selenious acid was shipped instead
of Selenium-75 labeled selenomethionine. In the other case Ytterbium-169
labeled chloride was shipped instead of Ytterbium-169 labeled
diethylenetriaminepentaacetic acid (DTPA).
The hospitals which received these materials should not have accepted them
since they were not authorized to possess them by their NRC license. In
addition, the hospital personnel preparing the patient doses should not have
prepared these materials for administration to a patient since the labels,
leaflets, and brochures in each case identified the radioisotope and
chemical form and included a warning that the radioactive material was not
for use in humans of clinical diagnosis.
Notice to Medical License
Medical licensees should have procedures to be followed by persons preparing
radiopharmaceutical for administration to humans. The procedures should
include the following steps:
a. confirmation that the compound is a radiopharmaceutical intended for
human use,
b. Verification that the type, chemical form and quantity of byproduct
material is the correct one for the particular patient and the medical
procedure being used, and
c. verification that the radiopharmaceutical was manufactured and
distributed under a license issued by the NRC or and Agreement State
.
IE Circular No.79-01 January 12, 1979
These confirmations and verifications can be accomplished by reviewing the
label, leaflets, and brochures enclosed int he package.
Medical licensees should instruct and require personnel to follow these
procedures in preparing and administering radiopharmaceutical to patients.
The contents of this Circular should be brought to the attention of all
personnel who prepare and administer licensed radiopharmaceutical to human
patients.
No written response to this Circular is required. If you require additional
information regarding this subject, please contact the Director of the
appropriate NRC Regional Office.
Page Last Reviewed/Updated Tuesday, March 09, 2021